M&A - Eli Lilly - Centessa Pharmaceuticals plc

Eli Lilly and Company has agreed to acquire Boston-based Centessa Pharmaceuticals in a deal aimed to advance the treatment of sleep-wake disorders. Lilly is paying approximately $6.3 billion, or $38 a share, upfront, with additional contingent payments of up to approximately $1.5 billion, or $9 a share. The transaction is expected to close in the third quarter. Eli Lilly is traded on the New York Stock Exchange, while Centessa is traded on the NASDAQ.

To add details to this portfolio regarding legal or economic representatives, please contact editors@mlex.com.

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login